Influence of hydrophilic additives on the supersaturation and bioavailability of dutasteride-loaded hydroxypropylβ-cyclodextrin nanostructures

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2029-2039

  Kim, Min Soo ^a  

^a Inje University   (South Korea)

Author keywords

Bioavailability; Dutasteride; Nanostructure; Solubility; Supercritical antisolvent

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; DUTASTERIDE; FINASTERIDE; NANOMATERIAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; EXPERIMENTAL RAT; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

BIOAVAILABILITY; DUTASTERIDE; NANOSTRUCTURE; SOLUBILITY; SUPERCRITICAL ANTISOLVENT;

ANALYSIS OF VARIANCE; ANIMALS; AZASTEROIDS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; KINETICS; MALE; NANOSTRUCTURES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SODIUM DODECYL SULFATE; SOLUBILITY;

EID: 84878073007     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S44795     Document Type: Review

References (40)

1. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol. 1999;47:53-58.
2. Evans HC, Goa KL. Dutasteride. Drugs Aging. 2003;20:905-916.
3. US Food Drug Administration. Center for Drug Evaluation and Research. Application Number 21-319. Clinical pharmacology and biopharmaceutics review. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21319_Duagen_biopharmr_P1.pdf. Accessed March 4, 2013.
4. Avodart® (product monograph). Middlesex, UK: GlaxoSmithKline. Available from: http://www.gsk.ca/english/docs-pdf/productmonographs/Avodart.pdf. Accessed March 4, 2013.
5. Ofner CM 3rd, Zhang YE, Jobeck VC, Bowman BJ. Crosslinking studies in gelatin capsules treated with formaldehyde and in capsules exposed to elevated temperature and humidity. J Pharm Sci. 2001;90: 79-88.
6. Beak IH, Kim MS. Improved supersaturation and oral absorption of dutasteride by amorphous solid dispersions. Chem Pharm Bull. 2012;60: 1468-1473.
7. Park SJ, Choo GH, Hwang SJ, Kim MS. Quality by design: screening of critical variables and formulation optimization of Eudragit E nanoparticles containing dutasteride. Arch Pharm Res. February 28, 2013. [Epub ahead of print.]
8. Choo GH, Park SJ, Hwang SJ, Kim MS. Formulation and in vivo evaluation of a self-microemulsifying drug delivery system of dutasteride. Drug Res (Stuttg). 2013;63:203-209.
9. Kim MS. Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs. Artif Cells Nanomed Biotechnol. January 22, 2013. [Epub ahead of print.]
10. Wang XQ, Fan JM, Liu YO, et al. Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. Int J Pharm. 2011;419:339-346.
11. Kawakami K. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs. Adv Drug Deliv Rev. 2012;64:480-495.
12. Ozaki S, Minamisono T, Yamashita T, Kato T, Kushida I. Supersaturation-nucleation behavior of poorly soluble drugs and its impact on the oral absorption of drugs in thermodynamically high-energy forms. J Pharm Sci. 2012;101:214-222.
13. Frank KJ, Rosenblatt KM, Westedt U, et al. Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: true supersaturation vs apparent solubility enhancement. Int J Pharm. 2012;437: 288-293.
14. Frank KJ, Westedt U, Rosenblatt KM, et al. The amorphous solid dispersion of the poorly soluble ABT-102 forms nano/microparticulate structures in aqueous medium: impact on solubility. Int J Nanomedicine. 2012;7:5757-5768.
15. Kim MS, Kim JS, Cho WK, et al. Supersaturatable formulations for the enhanced oral absorption of sirolimus. Int J Pharm. 2013;445: 108-116.
16. Overhoff KA, McConville JT, Yang W, et al. Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing. Pharm Res. 2008;25: 167-175.
17. Vandecruys R, Peeters J, Verreck G, Brewster ME. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int J Pharm. 2007;342:168-175.
18. Gao P, Shi Y. Characterization of supersaturatable formulations for improved absorption of poorly soluble drugs. AAPS J. 2012;14: 703-713.
19. Park JB, Lee GH, Kang JW, et al. Improvement of photostability and dissolution profile of isradipine using inclusion complex. J Pharm Investig. 2013;43:55-61.
20. Loftsson T, Másson M, Brewster ME. Self-association of cyclodextrins and cyclodextrin complexes. J Pharm Sci. 2004;93:1091-1099.
21. Loftsson T, Sigurdsson H, Masson M, Schipper N. Preparation of solid drug/cyclodextrin complexes of acidic and basic drugs. Pharmazie. 2004;59:25-29.
22. Xiang TX, Anderson BD. Stable supersaturated aqueous solutions of silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin via chemical conversion in the presence of a chemically modified beta-cyclodextrin. Pharm Res. 2002;19:1215-1222.
23. Brewster ME, Vandecruys R, Peeters J, et al. Comparative interaction of 2-hydroxypropyl-beta-cyclodextrin and sulfobutylether-beta-cyclodextrin with itraconazole: phase-solubility behavior and stabilization of supersaturated drug solutions. Eur J Pharm Sci. 2008;34:94-103.
24. Cha KH, Cho KJ, Kim MS, et al. Enhancement of the dissolution rate and bioavailability of fenofibrate by a melt-adsorption method using supercritical carbon dioxide. Int J Nanomedicine. 2012;7:5565-5575.
25. Kim JS, Kim MS, Park HJ, et al. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spraydrying and SAS process. Int J Pharm. 2008;359:211-219.
26. Kalivoda A, Fischbach M, Kleinebudde P. Application of mixtures of polymeric carriers for dissolution enhancement of oxeglitazar using hot-melt extrusion. Int J Pharm. 2012;439:145-156.
27. Kim MS, Jin SJ, Kim JS, et al. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm. 2008;69:454-465.
28. Kim MS, Kim JS, Park HJ, et al. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int J Nanomedicine. 2011;6:2997-3009.
29. Kim MS, Song HS, Park HJ, Hwang SJ. Effect of solvent type on the nanoparticle formation of atorvastatin calcium by the supercritical antisolvent process. Chem Pharm Bull. 2012;60:543-547.
30. Montes A, Gordillo MD, Pereyra C,Martínez de la Ossa EJ. Polymer and ampicillin co-precipitation by supercritical antisolvent process. J Supercrit Fluids. 2012;63:92-98.
31. Kim MS, Kim JS, Hwang SJ. Enhancement of wettability and dissolution properties of cilostazol using the supercritical antisolvent process: effect of various additives. Chem Pharm Bull. 2010;58:230-233.
32. Wen H, Morris KR, Park K. Hydrogen bonding interactions between adsorbed polymer molecules and crystal surface of acetaminophen. J Colloid Interface Sci. 2005;290:325-335.
33. Kojima T, Higashi K, Suzuki T, et al. Stabilization of a supersaturated solution of mefenamic acid from a solid dispersion with Eudragit(®) EPO. Pharm Res. 2012;29:2777-2791.
34. Magnusdottir A, Másson M, Loftsson T. Self association and cyclodextrin solubilization of NSAIDs. J Incl Phenom Macrocycl Chem. 2002;44:213-218.
35. Loftsson T, Magnúsdóttir A, Másson M, Sigurjónsdóttir JF. Self-association and cyclodextrin solubilization of drugs. J Pharm Sci. 2002;91:2307-2316.
36. Makhlof A, Miyazaki Y, Tozuka Y, Takeuchi H. Cyclodextrins as stabilizers for the preparation of drug nanocrystals by the emulsion solvent diffusion method. Int J Pharm. 2008;357:280-285.
37. Turnbull D, Fischer JC. Rate of nucleation in condensed systems. J Chem Phys. 1949;17:71-73.
38. US Food Drug Administration. Recommended dissolution methods. Available from: http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm. Accessed on March 4, 2013.
39. Gao P, Guyton ME, Huang T, et al. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev Ind Pharm. 2004;30:221-229.
40. Moes JJ, Koolen SL, Huitema AD, et al. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). Int J Pharm. 2011;420:244-250.